THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE
AMRYT PHARMA PLC
(“Amryt” or the “Company”)
AMRYT LISTED ON NASDAQ AND CEO TO RING NASDAQ CLOSING BELL
DUBLIN, Ireland, and Boston MA, July 8 2020, Amryt (Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announces that its American Depositary Shares (“ADSs”) are now trading on the Nasdaq Global Select Market (“Nasdaq”) under the symbol AMYT. Each ADS represents five of the Company’s ordinary shares (“Ordinary Shares”).
Amryt’s CEO, Dr Joe Wiley, will also virtually ring the Nasdaq closing bell today. The Amryt virtual closing bell ceremony will be broadcast live starting at 15:45 EDT (20:45 BST) from the Nasdaq MarketSite Tower in New York City.
To view the broadcast, please visit: https://livestream.com/accounts/27896496/events/9199306
Joe Wiley, CEO of Amryt, commented: “Listing on Nasdaq is a very important milestone for Amryt and will provide us with the opportunity to improve underlying liquidity in our shares, target a wider investor audience and increase our analyst coverage. With nearly 70% of our shareholders based in North America, listing on Nasdaq is an important part of our shareholder engagement and development plans. Furthermore, we believe our Nasdaq listing will significantly assist our efforts to drive value for all our stakeholders. Ringing the closing bell on Nasdaq is a great honour for all the Amryt team and we are very much looking forward to participating later today.”
A registration statement on Form F-1 was filed with the U.S. Securities and Exchange Commission (“SEC”) to facilitate the creation of a trading market in the United States for ADSs and in satisfaction of the Company’s obligations under a registration rights agreement entered into with certain investors who acquired Ordinary Shares in connection with the Company’s acquisition of Aegerion Pharmaceuticals, Inc. in September 2019. The Company has not issued any new securities in connection with this filing. The Ordinary Shares will continue to trade on the AIM market of the London Stock Exchange (“AIM”) and the Euronext Growth Market in Dublin (“Euronext”).
The Company also announces today that Mr. Ray Stafford (Company Chairman), Dr Joe Wiley (Company CEO) and Mr. Rory Nealon (Company CFO/COO) will be converting their Ordinary Shares into ADSs in the first month post listing on Nasdaq.
Citibank can accommodate all shareholders should they wish to convert their Ordinary Shares into ADSs. Should shareholders have any questions in relation to the mechanics of converting their Ordinary Shares into ADSs, they are advised to contact their broker.
Amryt has filed a registration statement (including a prospectus) with the SEC relating to its Ordinary Shares. You should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information. You may obtain these documents for free by visiting EDGAR on the SEC web site at www.sec.gov or from the Company at 160 Federal Street, 21st Floor, Boston, MA 02110. The registration statement relating to the Company’s ADSs was declared effective by the SEC. This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such jurisdiction. For the avoidance of doubt, the registration statement does not constitute a “prospectus” in the UK or in any member state of the European Economic Area (“EEA”) for the purposes of the Prospectus Regulation (Regulation (EU) 2017/1129) and has not been reviewed by any competent authority in the UK or in any member state of the EEA. No offer of securities to the public is being made in the UK or in any member state of the EEA.
|Amryt Pharma Plc||+353 (1) 518 0200|
|Joe Wiley, CEO
Rory Nealon, CFO/COO
|+44 (0) 20 7408 4090|
|NOMAD and Joint Broker|
|Edward Mansfield, Daniel Bush, John More|
|Stifel||+44 (0) 20 7710 7600|
|Jonathan Senior, Ben Maddison|
|Davy||+353 (1) 679 6363|
|ESM Adviser and Joint Broker|
|John Frain, Daragh O’Reilly|
Consilium Strategic Communications
+44 (0) 20 3709 5700
|Amber Fennell, Matthew Neal, Ashley Tapp|
LifeSci Advisors, LLC
|+1 (212) 915 2564|
This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014. The person making this notification on behalf of Amryt is Rory Nealon, CFO/COO and Company Secretary.
In the United Kingdom this announcement is directed only at (i) persons who have professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“Order”), (ii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) other persons to whom this announcement may otherwise lawfully be communicated (all such persons referred to in (i), (ii) and (iii) together being referred to as “relevant persons”). This document must not be acted or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with such persons.
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.
Amryt’s commercial business comprises two orphan disease products.
Statements in this announcement with respect to Amryt’s business, strategies, timing for completion of and announcing results from the EASE study, the potential impact of closing enrollment in the EASE study, as well as other statements that are not historical facts are forward-looking statements involving risks and uncertainties which could cause the actual results to differ materially from such statements. Statements containing the words “expect”, “anticipate”, “intends”, “plan”, “estimate”, “aim”, “forecast”, “project” and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Amryt’s present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond each of Amryt’s ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt’s ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information that may arise in connection with it. Such forward-looking statements reflect the Company’s current beliefs and assumptions and are based on information currently available to management.
A Global Asset Management Seoul Korea Magazine